Literature DB >> 29520739

The impact of ammonia levels and dialysis on outcome in 202 patients with neonatal onset urea cycle disorders.

Nina Hediger1, Markus A Landolt2,3, Carmen Diez-Fernandez1, Martina Huemer1,4, Johannes Häberle5.   

Abstract

Neonatal onset hyperammonemia in patients with urea cycle disorders (UCDs) is still associated with high morbidity and mortality. Current protocols consistently recommend emergency medical and dietary management. In case of increasing or persistent hyperammonemia, with continuous or progressive neurological signs, dialysis is performed, mostly as ultima ratio. It is presently unknown whether the currently defined ammonia threshold (e.g., at 500 μmol/L) to start dialysis is useful to improve clinical outcome. A systematic review of clinical and biochemical data from published neonatal onset UCD patients was performed to identify factors determining clinical outcome and to investigate in which clinical and biochemical setting dialysis was most effective. A total of 202 patients (118 proximal and 84 distal UCDs) described in 90 case reports or case series were included according to predefined inclusion/exclusion criteria. Median age at onset was three days and mean ammonia that triggered start of dialysis was 1199 μmol/L. Seventy-one percent of all patients received any form of dialysis. Total mortality was 25% and only 20% of all patients had a "normal" outcome. In general, patients with higher ammonia levels were more likely to receive dialysis, but this had for most patients no influence on outcome. In conclusion, in severe neonatal onset hyperammonemia, the current practice of dialysis, which effectively clears ammonia, had no impact on outcome. It may be essential for improving outcome to initiate all available treatment options, including dialysis, as early as possible.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29520739     DOI: 10.1007/s10545-018-0157-4

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  42 in total

1.  In defense of case reports and case series.

Authors:  J P Vandenbroucke
Journal:  Ann Intern Med       Date:  2001-02-20       Impact factor: 25.391

Review 2.  Diseases caused by defects of mitochondrial carriers: a review.

Authors:  Ferdinando Palmieri
Journal:  Biochim Biophys Acta       Date:  2008-03-25

3.  A biphasic dialytic strategy for the treatment of neonatal hyperammonemia.

Authors:  Mark Hanudel; Sonal Avasare; Eileen Tsai; Ora Yadin; Joshua Zaritsky
Journal:  Pediatr Nephrol       Date:  2014-02       Impact factor: 3.714

4.  Short-term survival of hyperammonemic neonates treated with dialysis.

Authors:  Stefano Picca; Carlo Dionisi-Vici; Andrea Bartuli; Tommaso De Palo; Francesco Papadia; Giovanni Montini; Marco Materassi; Maria Alice Donati; Enrico Verrina; Maria Cristina Schiaffino; Carmine Pecoraro; Emilia Iaccarino; Enrico Vidal; Alberto Burlina; Francesco Emma
Journal:  Pediatr Nephrol       Date:  2014-09-04       Impact factor: 3.714

5.  Successful prospective management of neonatal citrullinemia.

Authors:  Hayato Go; Takashi Imamura; Koichi Hashimoto; Kei Ogasawara; Osamu Sakamoto; Noriyuki Takubo; Nobuo Momoi; Mitsuaki Hosoya
Journal:  J Pediatr Endocrinol Metab       Date:  2012       Impact factor: 1.634

6.  A new case of arginase deficiency in a Spanish male.

Authors:  A Jordá; V Rubio; M Portolés; J Vilas; J García-Piño
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

Review 7.  Current role of liver transplantation for the treatment of urea cycle disorders: a review of the worldwide English literature and 13 cases at Kyoto University.

Authors:  Daisuke Morioka; Mureo Kasahara; Yasutsugu Takada; Yasumasa Shirouzu; Kaoru Taira; Seisuke Sakamoto; Kenji Uryuhara; Hiroto Egawa; Hiroshi Shimada; Koichi Tanaka
Journal:  Liver Transpl       Date:  2005-11       Impact factor: 5.799

8.  Hereditary urea cycle diseases in Finland.

Authors:  Päivi Keskinen; Anna Siitonen; Matti Salo
Journal:  Acta Paediatr       Date:  2008-07-09       Impact factor: 2.299

9.  Survival after treatment with phenylacetate and benzoate for urea-cycle disorders.

Authors:  Gregory M Enns; Susan A Berry; Gerard T Berry; William J Rhead; Saul W Brusilow; Ada Hamosh
Journal:  N Engl J Med       Date:  2007-05-31       Impact factor: 91.245

10.  Long-term outcomes in Ornithine Transcarbamylase deficiency: a series of 90 patients.

Authors:  Anais Brassier; Stephanie Gobin; Jean Baptiste Arnoux; Vassili Valayannopoulos; Florence Habarou; Manoelle Kossorotoff; Aude Servais; Valerie Barbier; Sandrine Dubois; Guy Touati; Robert Barouki; Fabrice Lesage; Laurent Dupic; Jean Paul Bonnefont; Chris Ottolenghi; Pascale De Lonlay
Journal:  Orphanet J Rare Dis       Date:  2015-05-10       Impact factor: 4.123

View more
  6 in total

1.  Peripheral venous route for administration of ammonul infusion for treatment of acute hyperammonemia. An experience from a tertiary center in Saudi Arabia.

Authors:  Amal M Alhashem; Rihab M Salih; Aida I Al-Aqeel; Sarar Mohamed
Journal:  Saudi Med J       Date:  2020-01       Impact factor: 1.484

Review 2.  CPS1: Looking at an ancient enzyme in a modern light.

Authors:  Matthew Nitzahn; Gerald S Lipshutz
Journal:  Mol Genet Metab       Date:  2020-10-10       Impact factor: 4.797

3.  Unmet Needs of Parents of Children with Urea Cycle Disorders.

Authors:  Mara Scharping; Heiko Brennenstuhl; Sven F Garbade; Beate Wild; Roland Posset; Matthias Zielonka; Stefan Kölker; Markus W Haun; Thomas Opladen
Journal:  Children (Basel)       Date:  2022-05-12

4.  Newborn metabolic vulnerability profile identifies preterm infants at risk for mortality and morbidity.

Authors:  Scott P Oltman; Elizabeth E Rogers; Rebecca J Baer; Elizabeth A Jasper; James G Anderson; Martina A Steurer; Matthew S Pantell; Mark A Petersen; J Colin Partridge; Deborah Karasek; Kharah M Ross; Sky K Feuer; Linda S Franck; Larry Rand; John M Dagle; Kelli K Ryckman; Laura L Jelliffe-Pawlowski
Journal:  Pediatr Res       Date:  2020-10-01       Impact factor: 3.756

5.  Characteristics of continuous venovenous hemodiafiltration in the acute treatment of inherited metabolic disorders.

Authors:  Fatma Tuba Eminoğlu; Ümmühan Öncül; Fevzi Kahveci; Emel Okulu; Elvis Kraja; Engin Köse; Tanıl Kendirli
Journal:  Pediatr Nephrol       Date:  2021-10-25       Impact factor: 3.651

6.  CRISPR-Mediated Genomic Addition to CPS1 Deficient iPSCs is Insufficient to Restore Nitrogen Homeostasis.

Authors:  Matthew Nitzahn; Brian Truong; Suhail Khoja; Agustin Vega-Crespo; Colleen Le; Adam Eliav; Georgios Makris; April D Pyle; Johannes Häberle; Gerald S Lipshutz
Journal:  Yale J Biol Med       Date:  2021-12-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.